To investigate the protective effect of dexmedetomidine combined with electroacupuncture on postoperative intestinal function in patients undergoing colorectal surgery

注册号:

Registration number:

ITMCTR2024000599

最近更新日期:

Date of Last Refreshed on:

2024-10-22

注册时间:

Date of Registration:

2024-10-22

注册号状态:

Registration Status:

补注册

Retrospective registration

注册题目:

探讨右美托咪定联合电针疗法对结直肠癌手术患者术后肠功能的保护作用

Public title:

To investigate the protective effect of dexmedetomidine combined with electroacupuncture on postoperative intestinal function in patients undergoing colorectal surgery

注册题目简写:

English Acronym:

研究课题的正式科学名称:

探讨右美托咪定联合电针疗法对结直肠癌手术患者术后肠功能的保护作用

Scientific title:

To investigate the protective effect of dexmedetomidine combined with electroacupuncture on postoperative intestinal function in patients undergoing colorectal surgery

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王晓刚

研究负责人:

王晓刚

Applicant:

Wang xiaogang

Study leader:

Wang xiaogang

申请注册联系人电话:

Applicant telephone:

15577208058

研究负责人电话:

Study leader's telephone:

15577208058

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

247326556@qq.com

研究负责人电子邮件:

Study leader's E-mail:

247326556@qq.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

广西柳州市解放北路32号

研究负责人通讯地址:

广西柳州市解放北路32号

Applicant address:

32 Jiefang North Road LiuzhouGuangxiChina

Study leader's address:

32 Jiefang North Road LiuzhouGuangxiChina

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

柳州市中医医院

Applicant's institution:

Liuzhou Traditional Chinese Medical Hospital

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2024MAR-KY-018-01

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

柳州市中医医院(柳州市壮医医院) 医学伦理委员会

Name of the ethic committee:

Ethics Committee of the Liuzhou Traditional Chinese Medical Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2024/3/1 0:00:00

伦理委员会联系人:

吴艳秋

Contact Name of the ethic committee:

Yanqiu Wu

伦理委员会联系地址:

广西柳州市解放北路32号

Contact Address of the ethic committee:

32 Jiefang North Road LiuzhouGuangxiChina

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 772 335 7722

伦理委员会联系人邮箱:

Contact email of the ethic committee:

721754367@qq.com

研究实施负责(组长)单位:

柳州市中医医院

Primary sponsor:

Liuzhou Traditional Chinese Medical Hospital

研究实施负责(组长)单位地址:

广西柳州市解放北路32号

Primary sponsor's address:

32 Jiefang North Road LiuzhouGuangxiChina

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广西

市(区县):

Country:

CHINA

Province:

GuangXi

City:

单位(医院):

柳州市中医医院

具体地址:

广西柳州市解放北路32号

Institution
hospital:

Liuzhou Traditional Chinese Medical Hospital

Address:

32 Jiefang North Road LiuzhouGuangxiChina

经费或物资来源:

自筹

Source(s) of funding:

self-financing

研究疾病:

结直肠癌

研究疾病代码:

Target disease:

colorectal cancer

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

探讨右美托嘧啶联合电针疗法对结直肠癌术后患者肠道功能恢复的效果。

Objectives of Study:

To investigate the protective effect of dexmedetomidine combined with electroacupuncture on postoperative intestinal function in patients undergoing colorectal surgery

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1、年龄大于18岁 2、病理诊断为结直肠恶性肿瘤 3、术前无放化疗、免疫辅助治疗和激素治疗史。

Inclusion criteria

1. Older than 18 years old 2. Colorectal malignant tumor was diagnosed by pathology 3. No history of chemoradiotherapy immune adjuvant therapy and hormone therapy before surgery.

排除标准:

1. 合并严重组织感染或组织免疫性疾病; 2. 合并严重器官功能障碍; 3. 合并精神疾病或沟通障碍。

Exclusion criteria:

1. Complicated with severe tissue infection or tissue immune disease; 2. Complicated with severe organ dysfunction; 3. Combined with mental illness or communication disorder.

研究实施时间:

Study execute time:

From 2024-07-01

To      2027-06-30

征募观察对象时间:

Recruiting time:

From 2024-07-01

To      2027-06-30

干预措施:

Interventions:

组别:

DEX联合针灸治疗组

样本量:

40

Group:

DA Group

Sample size:

干预措施:

DEX联合针灸治疗

干预措施代码:

Intervention:

Dexmedetomidine combined with electroacupuncture

Intervention code:

组别:

对照组

样本量:

40

Group:

control group

Sample size:

干预措施:

空白对照组

干预措施代码:

Intervention:

blank group

Intervention code:

组别:

DEX组

样本量:

40

Group:

D group

Sample size:

干预措施:

术中持续泵注右美托咪定

干预措施代码:

Intervention:

Dexmedetomidine was continuously pumped during the operation

Intervention code:

组别:

针灸治疗组

样本量:

40

Group:

A Group

Sample size:

干预措施:

电针治疗

干预措施代码:

Intervention:

Electroacupuncture

Intervention code:

样本总量 Total sample size : 160

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

广西壮族自治区

市(区县):

Country:

China

Province:

Guangxi Zhuang Autonomous Region

City:

单位(医院):

柳州市中医医院

单位级别:

三甲

Institution/hospital:

Liuzhou Traditional Chinese Medical Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

QoR-40量表评估 恢复质量

指标类型:

主要指标

Outcome:

QoR-40 scale to evaluate the quality of recovery

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

不良事件

指标类型:

主要指标

Outcome:

Adverse events

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肿瘤坏死因子-α

指标类型:

主要指标

Outcome:

Tumor necrosis factor-α

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

平均动脉压

指标类型:

主要指标

Outcome:

Mean arterial pressure

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

SAS量表评分

指标类型:

主要指标

Outcome:

SAS Scale score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

白细胞介素6

指标类型:

主要指标

Outcome:

Interleukin-6

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心率

指标类型:

主要指标

Outcome:

Heart rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

GSRS量表评分

指标类型:

主要指标

Outcome:

GSRS scale score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 18
Min age years
最大 90
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机数字表

Randomization Procedure (please state who generates the random number sequence and by what method):

Random number table

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

no

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

no

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

ase Record Form CRF

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above